Document Detail

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
MedLine Citation:
PMID:  22234255     Owner:  NLM     Status:  Publisher    
PURPOSE OF REVIEW: Ulceration of a primary cutaneous melanoma has for many years been recognized as a very important prognostic factor associated with increased risk for recurrence and mortality. Patients with an ulcerated melanoma do much worse than patients with a nonulcerated melanoma with the same breslow thickness. Ulceration may indicate a separate biologic entity. RECENT FINDINGS: Gene profiling studies of fresh frozen melanoma samples indicated that ulcerated melanomas have a very different profile. Analysis of the results of the two largest adjuvant interferon (IFN) trials ever conducted in 2644 patients [European Organization for Research and Treatment of Cancer (EORTC) 18952 and 18991], which used ulceration of the primary as a stratification factor, indicated that ulceration was not only a very strong prognostic factor, but more importantly a significant predictive factor for outcome of adjuvant IFN treatment. Only in patients with an ulcerated primary, was a similar and significant impact on disease-free survival, distant metastasis-free survival and overall survival observed. As a more general finding, in trials independent of ulceration used as a stratification factor, this IFN sensitivity of ulcerated melanomas has been reported in a meta-analysis in more than 3000 patients. It was also identified as a predictive factor of outcome in the Sunbelt adjuvant IFN trial in the USA. SUMMARY: These important findings regarding ulceration need biologic studies to identify the differences between ulcerated and nonulcerated melanoma at the molecular level. Moreover, the importance of ulceration will be assessed prospectively in the EORTC 18081 trial in patients with primary ulcerated melanomas more than 1 mm.
Alexander M M Eggermont; Alan Spatz; Vladimir Lazar; Caroline Robert
Related Documents :
15577435 - Treatment of recurrent merkel cell carcinoma: an analysis of 46 cases.
17960395 - Methylene blue halves the long-term recurrence rate in acute pilonidal sinus disease.
21605245 - Electrochemotherapy of cutaneous metastases of melanoma-a case series study and systema...
21875705 - Technique and outcomes of isolated limb infusion for locally advanced malignant melanom...
1985765 - Factors related to and consequences of weight loss in patients with stomach cancer. the...
19179555 - Soft tissue sarcomas of the trunk wall (sts-tw): a study of 343 patients from the frenc...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-9
Journal Detail:
Title:  Current opinion in oncology     Volume:  -     ISSN:  1531-703X     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
aInstitut de Cancérologie Gustave Roussy, Villejuif, Paris, France bSegal Cancer Centre, Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Merkel cell carcinoma: recent insights and new treatment options.
Next Document:  Ocular melanoma: what's new?